Chapter 22: Disorders of Hemostasis

The chapter establishes how the body normally achieves balance between preventing excessive bleeding and avoiding inappropriate clot formation, then explores the clinical consequences when this equilibrium is disrupted. The content addresses bleeding disorders such as hemophilia, explaining how deficiencies in clotting factors compromise the intrinsic coagulation pathway and impair the formation of stable fibrin clots. The chapter discusses therapeutic approaches to manage these conditions, including the use of desmopressin acetate, a synthetic vasopressin analog that enhances Factor VIII availability and improves hemostatic function in mild hemophilia cases by prolonging the survival of existing clotting factor molecules. The chapter also examines thrombotic disorders, which represent the opposite pathological extreme where excessive clot formation obstructs blood vessels and compromises tissue perfusion. Particular emphasis is placed on venous thromboembolism, including deep vein thrombosis and pulmonary embolism, conditions with substantial morbidity and mortality that occur with increased frequency in vulnerable populations including postoperative patients, immobilized individuals, and women in the postpartum period. The chapter integrates discussion of how acquired and inherited risk factors contribute to thrombosis development, how anticoagulant medications prevent and treat thromboembolic complications, and how clinicians balance the competing risks of bleeding and clotting when selecting therapeutic interventions. Understanding these hemostatic disorders is essential for recognizing clinical presentations, interpreting laboratory coagulation studies, and implementing appropriate therapeutic strategies across diverse clinical settings.